Czechia· CZ-0162697
GERODORM
A cinolazepam product containing cinolazepam, registered in Czechia by G.L. Pharma GmbH, Lannach.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
The record
At a glance
SÚKL (Czech Republic)- Active substance
- CINOLAZEPAM
- Manufacturer
- G.L. Pharma GmbH, Lannach
- Country
- Czechia (CZ)
- ATC code
- N05CD13
- ATC class
- Cinolazepam
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under N05CD13
Cinolazepam, as other registers publish it.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Austria · Gerodorm
- Bulgaria · Геродорм
- Hungary · Gerodorm
- Romania · Gerodorm
- Slovakia · Gerodorm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c93e1093-7215-4858-884c-ae32c18c8adf GET /v1/drugs/c93e1093-7215-4858-884c-ae32c18c8adf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL NOB",
"source": "sukl",
"strength": "40MG",
"pack_size": "10",
"substance": "CINOLAZEPAM",
"cz_kod_sukl": "0162697",
"product_type": "CH",
"substance_codes": "8915",
"registration_state": "R",
"registration_number": "57/186/96-C"
}See everything about cinolazepam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.